Associated Papers
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
41057686 (PubMed )
Supplement: 41375_2025_2774_MOESM2_ESM.xlsx › S3_-_SNVs__small_INDELS
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
40829168 (PubMed )
Supplement: BLOOD_BLD-2024-027692-mmc5.xlsx › Sheet_1
Genomic profiling of pediatric hematologic malignancies and diagnosis of cancer predisposition syndromes: tumoronly versus paired tumor-normal sequencing.
Newman H et al.
Haematologica, 2024
38385299 (PubMed )
Supplement: 2023_284855_NEWMAN_SUPPL.pdf
Aging and comprehensive molecular profiling in acute myeloid leukemia.
Li JF et al.
Proceedings of the National Academy of Sciences of the United States of America, 2024
38422020 (PubMed )
Supplement: pnas.2319366121.sd02.xlsx › Sheet_1
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
Hu Y et al.
Blood Advances, 2022
34710216 (PubMed )
Supplement: advancesADV2021006139-suppl1.pdf
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
Ferret Y et al.
Haematologica, 2018
29472349 (PubMed )
Supplement: 2017.183525.FERRET_SUPPL.pdf
Select a paper to view details